Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Massachusetts Institute of Technology | 38 |
| 2 | Ascendis Pharma AS | 29 |
| 3 | Harvard University | 28 |
| 4 | Fontem Ventures BV | 12 |
| 5 | University of South Florida St. Petersburg | 10 |
| 6 | Regeneron Pharmaceuticals Inc | 9 |
| 7 | Toray Industries Inc | 6 |
| 8 | Virginia Tech Intellectual Properties Inc | 6 |
| 9 | University of Florida Research Foundation Inc | 4 |
| 10 | Virginia Polytechnic Institute and State University | 4 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 244 |
| 2 | A61P | Therapeutic activity (drug indications) | 153 |
| 3 | C07K | Peptides | 140 |
| 4 | C12N | Microorganisms, enzymes | 112 |
| 5 | Y02A | Climate change adaptation | 30 |
| 6 | C12Y | Enzyme nomenclature (EC numbers) | 29 |
| 7 | C08J | Working-up of plastics | 18 |
| 8 | A61M | Devices for introducing media into the body | 16 |
| 9 | C12Q | Measuring/testing involving enzymes | 15 |
| 10 | A24F | 14 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| USE OF PEPTIDE Thr-Lys-Pro-Arg-Pro-Gly-Pro (SELANC) HEPATOPROTECTIVE FOR EXPOSURE IN ACUTE IMMOBILISATION STRESS | 2016 | Gosudarstvennoe bjudzhetnoe obrazovatelnoe uchrezhdenie vysshego professionalnogo obrazovanija "Kurskij gosudarstvennyj meditsinskij universitet" Ministerstva zdravookhranenija Rossijskoj Federatsii | 4 |
| APPLICATION OF Thr-Lys-Pro-Arg-Pro-Gly-Pro PEPTIDE (SELANK) FOR TOXIC HEPATITIS PREVENTION AND TREATMENT | 2017 | Obshchestvo s ogranichennoj otvetstvennostyu "Medanika" | 3 |
| USE OF THE PEPTIDE Thr-Lys-Pro-Arg-Pro-Gly-Pro (SELANK) TO INCREASE BODY RESISTANCE TO ACUTE HYPOTHERMIA | 2019 | Aktsionernoe obshchestvo "Innovatsionnyj nauchno-proizvodstvennyj tsentr "Peptogen" (AO "INPTS "Peptogen") | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Amino Acid Enzymes and Metabolism | 1 |
| 2 | Chemical and Physical Studies | 1 |
| 3 | Memory and Neural Mechanisms | 1 |
| 4 | Neurotransmitter Receptor Influence on Behavior | 1 |
| 5 | Stress Responses and Cortisol | 1 |
| 6 | Tryptophan and brain disorders | 1 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | N. F. Myasoedov | Institute of Molecular Genetics | 25 |
| 2 | Л. А. Андреева | Institute of Molecular Genetics | 17 |
| 3 | O. Yu. Sokolov | Mental Health Research Center of Russian Academy of Medical Sciences | 12 |
| 4 | Н. В. Кост | Mental Health Research Center of Russian Academy of Medical Sciences | 12 |
| 5 | И. И. Козловский | Institute of Pharmacology Russian Academy of Medical Sciences | 10 |
| 6 | Timur Kolomin | Institute of Molecular Genetics | 8 |
| 7 | Yu. A. Zolotarev | Institute of Molecular Genetics | 7 |
| 8 | М. И. Шадрина | Institute of Molecular Genetics | 7 |
| 9 | A. A. Zozulya | Mental Health Research Center of Russian Academy of Medical Sciences | 6 |
| 10 | Kozlovskaia Mm | 6 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Sedative‐Hypnotic Agents That Impact Gamma‐Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma‐Hydroxybutyric Acid, Phenibut, and Selank | 2021 | 25 | Neurotransmitter Receptor Influence on Behavior |
| Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission | 2016 | 19 | Neuroscience and Neuropharmacology Research |
| Selank and Short Peptides of the Tuftsin Family in the Regulation of Adaptive Behavior in Stress | 2003 | 19 | Neurotransmitter Receptor Influence on Behavior |
| The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity | 2001 | 15 | Stress Responses and Cortisol |
| Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential for their practical application | 2006 | 13 | Receptor Mechanisms and Signaling |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Selank?
Which institutions hold the most patents related to Selank?
What are the primary research topics associated with Selank in the academic literature?
Which patent classification codes are most prominent in Selank-related intellectual property?
Who are the leading researchers publishing on Selank?